단백질 변성 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global protein degeneration therapy market size is expected to reach USD 3.70 Billion in 2034 from USD 1.75 Billion in 2025, growing at a CAGR of 8.67 during 2026-2034.This market has gained momentum as healthcare providers and researchers focus on treating diseases associated with abnormal protein accumulation and degeneration. Advances in biotechnology and molecular medicine have improved understanding of protein-related disorders, creating opportunities for innovative therapeutic approaches. Growing prevalence of neurodegenerative and rare diseases has further increased demand for targeted treatment solutions.

The market is driven by rising investments in biomedical research, expanding clinical development programs, and growing awareness of protein-related disorders. Pharmaceutical companies are exploring advanced therapies designed to address underlying disease mechanisms rather than merely managing symptoms. Supportive regulatory initiatives and increased funding for rare disease research are also contributing to market growth.

Future prospects are highly promising as breakthroughs in gene therapy, precision medicine, and biologics continue advancing treatment possibilities. Ongoing clinical trials and technological innovations are expected to improve therapeutic effectiveness and patient outcomes. As scientific understanding of protein degeneration disorders expands, the market is likely to witness significant long-term growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Bavdegalutamide (ARV-110)
• Vepdegestrant (ARV-471)
• Other Types

By Application

• Oncology
• Neurodegenerative Diseases
• Infectious Diseases
• Other Applications

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Academic and Research Institutes

COMPANIES PROFILED

• Arvinas Holding Company LLC, Relay Therapeutics Inc., Kymera Therapeutics Inc., Nurix Therapeutics Inc., Vividion Therapeutics Inc., Mission Therapeutics Ltd., C4 Therapeutics Inc., Frontier Medicines Inc., Foghorn Therapeutics Inc., Aileron Therapeutics Inc., Ribometrix Inc., Nimbus Therapeutics Inc., Jnana Therapeutics Inc., KSQ Therapeutics Inc., Stoke Therapeutics Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PROTEIN DEGENERATION THERAPY MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Bavdegalutamide (ARV-110) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Vepdegestrant (ARV-471) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Other Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PROTEIN DEGENERATION THERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Neurodegenerative Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PROTEIN DEGENERATION THERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PROTEIN DEGENERATION THERAPY MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PROTEIN DEGENERATION THERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Relay Therapeutics Inc
  • 9.2.2 Kymera Therapeutics Inc
  • 9.2.3 Nurix Therapeutics Inc
  • 9.2.4 Vividion Therapeutics Inc
  • 9.2.5 Mission Therapeutics Ltd
  • 9.2.6 C4 Therapeutics Inc
  • 9.2.7 Frontier Medicines Inc
  • 9.2.8 Foghorn Therapeutics Inc
  • 9.2.9 Aileron Therapeutics Inc
  • 9.2.10 Ribometrix Inc
  • 9.2.11 Nimbus Therapeutics Inc
  • 9.2.12 Jnana Therapeutics Inc
  • 9.2.13 KSQ Therapeutics Inc
  • 9.2.14 Stoke Therapeutics Inc